Hardik B. Patel

Safety and Immunogenicity of a DNA SARS-CoV-2 vaccine (ZyCoV-D): Results of an open-label, non-randomized phase I part of phase I/II clinical study by intradermal route in healthy subjects in India

Taufik Momin, Kevinkumar Kansagra, Hardik B. Patel et al. · EClinicalMedicine · 2021 · 183 citations · Full text

Veterinary Medicine, Immunology, Infectious Diseases +17

Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of the Oral NLRP3 Inflammasome Inhibitor ZYIL1: First‐in‐Human Phase 1 Studies (Single Ascending Dose and Multiple Ascending Dose)

Kevinkumar Kansagra, Taufik Momin, Hardik B. Patel et al. · Clinical Pharmacology in Drug Development · 2022 · 73 citations · Full text

Medicine, Pharmacokinetics, Pharmacology +13

Phase I Clinical Study of ZYAN1, A Novel Prolyl-Hydroxylase (PHD) Inhibitor to Evaluate the Safety, Tolerability, and Pharmacokinetics Following Oral Administration in Healthy Volunteers

Kevinkumar Kansagra, Rajendrakumar H. Jani, Nuggehally R. Srinivas et al. · Clinical Pharmacokinetics · 2017 · 38 citations · Full text

Pharmacy, Pharmacokinetics, Pharmacology +14

Safety, pharmacokinetics, and antimalarial activity of the novel triaminopyrimidine ZY-19489: a first-in-human, randomised, placebo-controlled, double-blind, single ascending dose study, pilot food-effect study, and volunteer infection study.

Bridget E. Barber, Melissa Fernandez, Hardik B. Patel et al. · LSTM Online Archive (Liverpool School of Tropical Medicine) · 2022 · 30 citations

Medicine, Pharmacokinetics, Pharmacology +16

Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of ZY‐IL1 in Three Patients with Cryopyrin‐Associated Periodic Syndromes

Pravin Hissaria, Kevinkumar Kansagra, Hardik B. Patel et al. · Clinical Pharmacology in Drug Development · 2023 · 30 citations · Full text

Medicine, Pharmacokinetics, Pharmacology +14